July 16 Financial Quick Takes: J&J growth drivers beat consensus; plus Notable and Cradle raise funds
Imbruvica, Darzalex sales top analysts' consensus
In its 2Q19 earnings report, Johnson & Johnson (NYSE:JNJ) said revenue from its pharmaceutical segment grew to $10.53 billion during the quarter, up 1.7% compared with 2Q18, with newer blockbusters Imbruvica ibrutinib and Darzalex daratumumab each beating consensus estimates. Sales of Imbruvica were $831 million during the quarter, coming in ahead of analysts' $804.3 million estimate; Darzalex delivered $774 million, beating the $691.7 million consensus. J&J also raised its full-year revenue guidance to $82.4-$83.2 billion from $82-$82.8 billion; analysts were expecting about $81.2 million.
Precision medicine play Notable nabs $40M B round
Notable Labs Inc. (Foster City, Calif.) raised $40 million in a series B round led by new investor B Capital Group and existing backer LifeForce Capital. The company is developing a platform to identify patients most likely to respond to oncology therapies in clinical trials. Industry Ventures also participated in the round...